LM22A-4 is a small molecule BDNF mimetic that act as a direct and specific partial agonist of TrkB (EC50=200-500 pM), but not other Trks or p75(NTR).
LM22A-4 prevents neuronal degeneration with efficacy equal to that of BDNF in vitro models of neurodegenerative disease.
LM22A-4 causes hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats.
LM22A-4 reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.
